The test is conducted with the patient awake. Essentially, a barbiturate (which is usually sodium amobarbital) is introduced into one of the internal carotid arteries via a cannula or intra-arterial catheter from the femoral artery. The drug is injected into one hemisphere at a time. The effect is to shut down any language and/or memory function in that hemisphere in order to evaluate the other hemisphere ("half of the brain"). Then the patient is engaged in a series of language and memory related tests. The memory is evaluated by showing a series of items or pictures to the patient so that within a few minutes as soon as the effect of the medication is dissipated, the ability to recall can be tested.
There is currently great variability in the processes used to administer the test, and so it is difficult to compare results from one patient to the other.
The test is usually performed prior to ablative surgery for epilepsy and sometimes prior to tumor resection. The aim is to determine which side of the brain is responsible for certain vital cognitive functions, namely speech and memory. The risk of damaging such structures during surgery can then be assessed, and the need for awake craniotomies can be determined as well.
The Wada test has several interesting side-effects. Drastic personality changes are rarely noted, but disinhibition is common. Also, contralateral hemiplegia, hemineglect and shivering are often seen. During one injection, typically the left hemisphere, the patient will have impaired speech or be completely unable to express or understand language. Although the patient may not be able to talk, sometimes their ability to sing is preserved. This is because music and singing utilizes a different part of your brain than speech and language. Most people with aphasia are able to sing, and even learn new songs (as in the case of Cesero Rota, klawans, 2002).Recovery from the anesthesia is rapid, and EEG recordings and distal grip strength are used to determine when the medication has worn off. Generally, recovery of speech is dysphasic (contains errors in speech or comprehension) after a dominant hemisphere injection. Although generally considered a safe procedure, there are at least minimal risks associated with the angiography procedure used to guide the catheter to the internal carotid artery. As such, efforts to utilize non-invasive means to determine language and memory laterality (e.g. fMRI) are being researched.
The Wada test is named after Canadian neurologist Juhn A. Wada, of the University of British Columbia. He developed the test while a medical resident in Japan just after World War II, when he was receiving training in neurosurgery. Recognizing that there was no available test for cerebral dominance for speech, Wada developed the carotid amytal test. He published the initial description in 1949, in Japanese. During later training at the Montreal Neurological Institute, he introduced the test to the English-speaking world.
- Hermann B (2005). "Wada test failure and cognitive outcome". Epilepsy currents / American Epilepsy Society. 5 (2): 61–2. doi:10.1111/j.1535-7597.2005.05206.x. PMID 16059438.
- synd/3813 at Who Named It
- J. Wada. A new method for the determination of the side of cerebral speech dominance. A preliminary report of the intra-carotid injection of sodium amytal in man. Igaku to Seibutsugaki, Tokyo, 1949, 14, 221-222.
- Wada Testing
- "The Johns Hopkins Epilepsy Center". Retrieved 2007-06-05.
- Image at University of Hong Kong